Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.
Also called NCT04029363
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT04029363
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia, Belgium, France, Germany, Poland, Singapore, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT04029363. Allocation not applicable; no masking; primary purpose treatment. Start 2019-05-28 (actual); primary completion 2026-12-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk
- Condition
- Mitral Regurgitation
- Intervention (Device)
- HighLife Transcatheter Mitral Valve Replacement
- Lead sponsor
- HighLife SAS
- Collaborator
- ICON plc
Record details
- Record id
cardio:ct-nct04029363- Content hash
d58b5f55290c282ebeab51a66376f03f04af884d66ce88543a220c3eedf9b8fe